Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
EXORPHIA Logo
EXORPHIA Growth Score
77
CB Rank
91410
Heat Score
55
EXORPHIA is a biotech startup that develops novel medicine using extracellular vesicles.
Founded
obfuscation
PrivateCorporate Round Otemachi, Tokyo, Japan11-50 exorphia.com/
Biotechnology
Manufacturing
Product Research
Overview

EXORPHIA
Total Funding
obfuscation
Growth Score
77
Heat Score
55

Total Funding
obfuscation
Corporate Round raised
obfuscation
Growth Score77
-16 pts
in past quarter
Heat Score 55
-34 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About EXORPHIA

CB Rank
91410
EXORPHIA is a biotech startup that develops novel medicine using extracellular vesicles.
Founded
obfuscation
PrivateCorporate Round Otemachi, Tokyo, Japan11-50 exorphia.com/
Biotechnology
Manufacturing
Product Research

Funding Rounds

Corporate Round
OBF
in
obfuscation
Seed
OBF
in
obfuscation
Seed
OBF
in
obfuscation

Key People

  • Photo of Koji Kuchiishi
    Koji Kuchiishi: Founder, Chairman, and Chief Executive Officer
    Past Role: Cyfuse Biomedical, Co-Founder & CEO

Details

Legal Name EXORPHIA Inc.
Also Known As エクソーフィア
Operating Status Active
Company Type For Profit
Founders  Koji Kuchiishi
About the Company

EXORPHIA is a biotechnology startup focused on creating innovative medicines through the use of extracellular vesicles. The company is involved in the research, development, production, and marketing of exosome-based drugs derived from human cells. EXORPHIA operates in two primary sectors: the Drug Discovery Business, which seeks to commercialize

exosomes for pharmaceutical applications, and the Non-Drug Discovery Business, which markets exosomes as raw materials for non-medical products.

Contact Email privacy@exorphia.com
Predictions & Insights

Growth Insight

See this Growth Insight
EXORPHIA is
Lorem
 to be growing
Top Contributing Factors
Recently Raised Funding

Growth Prediction

See this Growth Prediction
Top Contributing Factors
Runway Speculation

Products & Services

EXP01
An extracellular vesicle (EV) formulation derived from bone marrow mesenchymal stem cells for treating inflammatory and fibrotic diseases such as lung disorders, atopic dermatitis, and chronic kidney disease.
EXP02
An EV formulation derived from umbilical cord mesenchymal stem cells intended as an additive to in vitro fertilization (IVF) culture media to improve embryo development and IVF success rates.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 3
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Corporate Round - EXORPHIA Logo
Corporate Round - EXORPHIA
1
obfuscation
Rohto PharmaceuticalCorporate Round
obfuscation
Corporate Round - EXORPHIA Logo
Corporate Round - EXORPHIA
1
obfuscation
Rohto PharmaceuticalCorporate Round
obfuscation
Corporate Round - EXORPHIA Logo
Corporate Round - EXORPHIA
1
obfuscation
Rohto PharmaceuticalCorporate Round
obfuscation
Corporate Round - EXORPHIA Logo
Corporate Round - EXORPHIA
1
obfuscation
Rohto PharmaceuticalCorporate Round
obfuscation
Corporate Round - EXORPHIA Logo
Corporate Round - EXORPHIA
1
obfuscation
Rohto PharmaceuticalCorporate Round

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 3
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Corporate Round - EXORPHIA Logo
Corporate Round - EXORPHIA
1
obfuscation
Rohto PharmaceuticalCorporate Round
obfuscation
Corporate Round - EXORPHIA Logo
Corporate Round - EXORPHIA
1
obfuscation
Rohto PharmaceuticalCorporate Round
obfuscation
Corporate Round - EXORPHIA Logo
Corporate Round - EXORPHIA
1
obfuscation
Rohto PharmaceuticalCorporate Round
obfuscation
Corporate Round - EXORPHIA Logo
Corporate Round - EXORPHIA
1
obfuscation
Rohto PharmaceuticalCorporate Round
obfuscation
Corporate Round - EXORPHIA Logo
Corporate Round - EXORPHIA
1
obfuscation
Rohto PharmaceuticalCorporate Round

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.
Investor Name  
Lead Investor  
Funding Round  
Partners  
Rohto Pharmaceutical Logo
Rohto Pharmaceutical
Yes
Corporate Round - EXORPHIA Logo
Corporate Round - EXORPHIA
—
Rohto Pharmaceutical Logo
Rohto Pharmaceutical
Yes
Corporate Round - EXORPHIA Logo
Corporate Round - EXORPHIA
—
Rohto Pharmaceutical Logo
Rohto Pharmaceutical
Yes
Corporate Round - EXORPHIA Logo
Corporate Round - EXORPHIA
—
Rohto Pharmaceutical Logo
Rohto Pharmaceutical
Yes
Corporate Round - EXORPHIA Logo
Corporate Round - EXORPHIA
—
Rohto Pharmaceutical Logo
Rohto Pharmaceutical
Yes
Corporate Round - EXORPHIA Logo
Corporate Round - EXORPHIA
—
Market Intelligence
People
View Profiles & Contacts
Headcount 11-50 Employee Profiles 1

Employee Profiles

News

News and Press

News•Mar 12, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Mar 3, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Aug 21, 2025
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

412

Active Website Tech Count

5EXORPHIA is actively using 5 technologies for its website, according to BuiltWith. These include Euro, CommonCrawl Top 5m, and  Pound Sterling.

Total IP

4The intellectual property of EXORPHIA includes 4 registered patents primarily in the 'Biochemistry; Beer; Spirits; Wine; Vinegar; Microbiology; Enzymology; Mutation Or Genetic Engineering' category, according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is EXORPHIA's headquarters? EXORPHIA is located in Otemachi, Tokyo, Japan.Who invested in EXORPHIA? EXORPHIA has 3 investors including Rohto Pharmaceutical and  Keio Innovation Initiative.When was the last funding round for EXORPHIA? EXORPHIA closed its last funding round on
obfuscation
from a Corporate Round round.Who are EXORPHIA's competitors? Alternatives and possible competitors to EXORPHIA may include Canton Strategic Holdings, Capricor Therapeutics, and  Evox Therapeutics.How much funding has EXORPHIA raised to date? EXORPHIA has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(3e39328 1)
|